Medscape Dermatology asked Steven R. Feldman, MD, PhD, professor of dermatology at Wake Forest University School of Medicine, Winston-Salem, North Carolina, to share his expertise on the impact ...

The Biosimilars Access and Affordability Act (H.R. 10628/S. 5571) has been reintroduced in both the House and Senate. The bill would alter ...

(MENAFN- GlobeNewsWire - Nasdaq) As biologics lose exclusivity, the strategic advantage is moving beyond R&D toward deciding which molecules to pursue, where to compete and how to protect economics ...

The Inflation Reduction Act (IRA) has reshaped how Medicare covers and reimburses prescription drugs. For the first time, the federal government established prices for ten drugs selected through the ...

Each of the several bipartisan bills being considered by Congress to promote biosimilar competition would have major ...

Dublin, Sept. 12, 2025 (GLOBE NEWSWIRE) -- The "Oncology Biosimilars Market Report by Drug Type, and Region 2025-2033" has been added to ResearchAndMarkets.com's offering. The global oncology ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Biocon Biologics Merger with Biocon: Biocon is sharpening its global biosimilars strategy with a renewed focus on consolidation, cost optimisation and long-term capex planning. In a conversation with ...

Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, is thrilled to announce the signing of a landmark licensing agreement with ...

CHICAGO--(BUSINESS WIRE)--Meitheal Pharmaceuticals, Inc. (“Meitheal”), a fully integrated biopharmaceutical company based in Chicago and focused on the development and commercialization of generic ...

The US drugmaker is building on Kashiv BioSciences' biologics capabilities to expand its India play across biosimilars, complex medicines, manufacturing and R&D.

Formycon AG is betting big on high?value biosimilars for blockbuster biologics like Eylea and Stelara. Here’s how its focused pipeline, technology, and deals are reshaping the market. For all the hype ...